The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Hormone Research in Paediatrics, published by KARGER, is a leading international journal dedicated to advancing the field of pediatric endocrinology. With its ISSN 1663-2818 and E-ISSN 1663-2826, it serves as a vital resource for researchers and professionals focused on the hormonal aspects affecting children's health. Housed in Switzerland, the journal benefits from a strong academic reputation and ranks in the prestigious Q1 category in Pediatrics, Perinatology, and Child Health, as well as maintaining Q2 status in Endocrinology, Diabetes, and Metabolism. Covering a time span from its inception in 1970 to the present day, Hormone Research in Paediatrics is committed to publishing high-quality original research, reviews, and clinical studies, making crucial contributions to our understanding of pediatric hormonal disorders and treatments. The journal incorporates open access options, fostering wider dissemination and accessibility of vital research findings, thus ensuring that significant advancements reach academics, professionals, and students globally.

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.